MA-BRIGHTCOVE
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced two additions and a newly formed role to its executive leadership team. Kathy Klingler has been appointed Chief Marketing Officer (CMO), and Jim Norton as Chief Revenue Officer (CRO), effective January 8, 2024. Additionally, Brightcove’s current Chief Strategy and Corporate Development Officer, David Beck, is taking on an expanded role as Chief Operating Officer (COO).
“With the addition of Kathy and Jim and the evolution of David’s role, our world-class executive leadership team is poised to continue to deliver for our global customer base and drive innovation across our business,” said Brightcove CEO Marc DeBevoise. “Each of them brings an invaluable skill set from across the media, enterprise, and SaaS industries that will play a key role in our continued growth and further establish Brightcove as the world's most trusted streaming technology company.”
As CMO, Klingler will be responsible for developing and executing a global marketing strategy that leverages data, insights, creativity, and connectivity to drive growth, boost brand awareness, increase customer acquisition, and expand customer loyalty. She brings a record of global success to Brightcove, having previously held senior marketing leadership roles at large enterprise organizations in varying sectors, including Blue Cross Blue Shield of MA, Santander Bank, KPMG, Fidelity Investments, John Hancock, Kaplan Higher Education, and cybersecurity software company Rapid7. She will report directly to Brightcove CEO Marc DeBevoise.
“I am thrilled to join Brightcove to continue its unparalleled leadership in the streaming technology space,” said Klingler. “Throughout my career, I’ve prioritized crafting compelling strategies that connect with people and drive tangible results. I look forward to advancing that work with my new colleagues as we chart our company’s promising future.”
As the CRO, Norton will be responsible for Brightcove’s revenue organization, including managing global sales and customer success and driving and executing the company’s go-to-market strategy. Norton brings over 20 years of sales leadership experience in media, advertising, SaaS, and marketing technology at leading companies such as Condé Nast, AOL/Verizon, Google, Tribune Broadcasting, and Flowcode. He will report directly to DeBevoise.
“Throughout my career, I’ve had the opportunity to work across various verticals and sectors on a global scale. Brightcove represents the perfect intersection of all that I have been working towards, and I can't think of a better fit,” said Norton. “I’m enthusiastic about joining this exceptional leadership team and leveraging our heritage as the world’s most trusted streaming company as we grow global sales and revenue generation.”
David Beck has served as Chief Strategy and Corporate Development Officer and interim CMO. In addition to his current role, he has assumed new and expanded responsibilities as COO. As the Chief Operating Officer, Beck’s responsibilities include corporate development and strategy, technology and channel partnerships, data engineering, strategy and analytics, revenue and marketing operations, and ad monetization. He will be focused on advancing the execution of Brightcove’s strategy, driving operational excellence, fostering greater cross-functional collaboration throughout the organization, and leading growth and operational transformation initiatives.
For more information, visit Brightcove.com.
About Brightcove, Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow on LinkedIn, Twitter, Facebook, Instagram and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219310496/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Expands its Natural Ingredients Portfolio with the Launch of Coloring Foodstuffs and Natural Colors Product Lines, Enhancing Innovation in Upcycled Products16.7.2025 12:18:00 CEST | Press release
Prodalim, a global leader in juice solutions and specialty ingredients, announces the launch of its Coloring Foodstuffs and Natural Colores portfolio, marking a milestone in its commitment to delivering clean-label, plant-based, upcycled product innovations for the food and beverage industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716821011/en/ These natural color solutions are designed for seamless integration into a wide range of applications, including beverages, dairy, plant-based products, bakery, and confectionery. They offer vibrant visual appeal without compromising on performance, health standards, regulatory compliance, or consumer trust. Developed based on strict quality standards, Prodalim’s Coloring portfolio delivers optimal light resistance, pH stability, and thermal performance, addressing real-world formulation challenges while enhancing naturality, clean label credentials, and full “tree-to-table
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom